Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 370

1.

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose.

Jilg S, Hauch RT, Kauschinger J, Buschhorn L, Odinius TO, Dill V, Müller-Thomas C, Herold T, Prodinger PM, Schmidt B, Hempel D, Bassermann F, Peschel C, Götze KS, Höckendorf U, Haferlach T, Jost PJ.

Exp Hematol Oncol. 2019 Apr 16;8:9. doi: 10.1186/s40164-019-0133-1. eCollection 2019.

2.

Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).

Jilg S, Rassner M, Maier J, Waldeck S, Kehl V, Follo M, Philipp U, Sauter A, Specht K, Mitschke J, Lange T, Bauer S, Jost PJ, Peschel C, Duyster J, Gaiser T, Hohenberger P, von Bubnoff N.

Int J Cancer. 2019 Oct 15;145(8):2292-2303. doi: 10.1002/ijc.32282. Epub 2019 Apr 29.

PMID:
30882891
3.

Cancer clinical trials - Survey evaluating patient participation and acceptance in a university-based Comprehensive Cancer Center (CCC).

Kessel KA, Vogel MME, Kessel C, Bier H, Biedermann T, Friess H, Herschbach P, von Eisenhart-Rothe R, Meyer B, Kiechle M, Keller U, Peschel C, Bassermann F, Schmid R, Schwaiger M, Combs SE.

Clin Transl Radiat Oncol. 2018 Oct 4;13:44-49. doi: 10.1016/j.ctro.2018.10.001. eCollection 2018 Nov.

4.

Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia.

Mangolini M, Götte F, Moore A, Ammon T, Oelsner M, Lutzny-Geier G, Klein-Hitpass L, Williamson JC, Lehner PJ, Dürig J, Möllmann M, Rásó-Barnett L, Hughes K, Santoro A, Méndez-Ferrer S, Oostendorp RAJ, Zimber-Strobl U, Peschel C, Hodson DJ, Schmidt-Supprian M, Ringshausen I.

Nat Commun. 2018 Sep 21;9(1):3839. doi: 10.1038/s41467-018-06069-5.

5.

Evaluation of the new continuous mononuclear cell collection protocol versus an older version on two different apheresis machines.

Spoerl S, Wäscher D, Nagel S, Peschel C, Verbeek M, Götze K, Krackhardt AM.

Transfusion. 2018 Jul;58(7):1772-1780. doi: 10.1111/trf.14644. Epub 2018 May 6.

PMID:
29732573
6.

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.

Reidel V, Kauschinger J, Hauch RT, Müller-Thomas C, Nadarajah N, Burgkart R, Schmidt B, Hempel D, Jacob A, Slotta-Huspenina J, Höckendorf U, Peschel C, Kern W, Haferlach T, Götze KS, Jilg S, Jost PJ.

Oncotarget. 2018 Apr 3;9(25):17270-17281. doi: 10.18632/oncotarget.24775. eCollection 2018 Apr 3.

7.

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.

Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson JE, Bourhis JH, Krejci M, Leleu X, Potter M, Blaise D, Koenecke C, Peschel C, Radocha J, Metzner B, Lenain P, Schäfer-Eckart K, Pohlreich D, Grasso M, Caillot D, Einsele H, Ladetto M, Schönland S, Kröger N.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1372-1378. doi: 10.1016/j.bbmt.2018.01.035. Epub 2018 Feb 3.

8.

Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.

Garz AK, Wolf S, Grath S, Gaidzik V, Habringer S, Vick B, Rudelius M, Ziegenhain C, Herold S, Weickert MT, Smets M, Peschel C, Oostendorp RAJ, Bultmann S, Jeremias I, Thiede C, Döhner K, Keller U, Götze KS.

Oncotarget. 2017 Oct 16;8(65):108738-108759. doi: 10.18632/oncotarget.21877. eCollection 2017 Dec 12.

9.

Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics.

Habringer S, Lapa C, Herhaus P, Schottelius M, Istvanffy R, Steiger K, Slotta-Huspenina J, Schirbel A, Hänscheid H, Kircher S, Buck AK, Götze K, Vick B, Jeremias I, Schwaiger M, Peschel C, Oostendorp R, Wester HJ, Grigoleit GU, Keller U.

Theranostics. 2018 Jan 1;8(2):369-383. doi: 10.7150/thno.21397. eCollection 2018.

10.

Cluster Formation of Polyphilic Molecules Solvated in a DPPC Bilayer.

Guo XY, Peschel C, Watermann T, Rudorff GFV, Sebastiani D.

Polymers (Basel). 2017 Oct 6;9(10). pii: E488. doi: 10.3390/polym9100488.

11.

Polyphilic Interactions as Structural Driving Force Investigated by Molecular Dynamics Simulation (Project 7).

Peschel C, Brehm M, Sebastiani D.

Polymers (Basel). 2017 Sep 14;9(9). pii: E445. doi: 10.3390/polym9090445. Review.

12.

A20 Restrains Thymic Regulatory T Cell Development.

Fischer JC, Otten V, Kober M, Drees C, Rosenbaum M, Schmickl M, Heidegger S, Beyaert R, van Loo G, Li XC, Peschel C, Schmidt-Supprian M, Haas T, Spoerl S, Poeck H.

J Immunol. 2017 Oct 1;199(7):2356-2365. doi: 10.4049/jimmunol.1602102. Epub 2017 Aug 25.

13.

A20 deletion in T cells modulates acute graft-versus-host disease in mice.

Fischer JC, Otten V, Steiger K, Schmickl M, Slotta-Huspenina J, Beyaert R, van Loo G, Peschel C, Poeck H, Haas T, Spoerl S.

Eur J Immunol. 2017 Nov;47(11):1982-1988. doi: 10.1002/eji.201646911. Epub 2017 Sep 15.

14.

In-depth Characterization of a TCR-specific Tracer for Sensitive Detection of Tumor-directed Transgenic T Cells by Immuno-PET.

Yusufi N, Mall S, Bianchi HO, Steiger K, Reder S, Klar R, Audehm S, Mustafa M, Nekolla S, Peschel C, Schwaiger M, Krackhardt AM, D'Alessandria C.

Theranostics. 2017 Jun 15;7(9):2402-2416. doi: 10.7150/thno.17994. eCollection 2017.

15.

Mobile Health in Oncology: A Patient Survey About App-Assisted Cancer Care.

Kessel KA, Vogel MM, Kessel C, Bier H, Biedermann T, Friess H, Herschbach P, von Eisenhart-Rothe R, Meyer B, Kiechle M, Keller U, Peschel C, Schmid RM, Combs SE.

JMIR Mhealth Uhealth. 2017 Jun 14;5(6):e81. doi: 10.2196/mhealth.7689.

16.

RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury.

Fischer JC, Bscheider M, Eisenkolb G, Lin CC, Wintges A, Otten V, Lindemans CA, Heidegger S, Rudelius M, Monette S, Porosnicu Rodriguez KA, Calafiore M, Liebermann S, Liu C, Lienenklaus S, Weiss S, Kalinke U, Ruland J, Peschel C, Shono Y, Docampo M, Velardi E, Jenq RR, Hanash AM, Dudakov JA, Haas T, van den Brink MRM, Poeck H.

Sci Transl Med. 2017 Apr 19;9(386). pii: eaag2513. doi: 10.1126/scitranslmed.aag2513.

17.

Card9 controls Dectin-1-induced T-cell cytotoxicity and tumor growth in mice.

Haas T, Heidegger S, Wintges A, Bscheider M, Bek S, Fischer JC, Eisenkolb G, Schmickl M, Spoerl S, Peschel C, Poeck H, Ruland J.

Eur J Immunol. 2017 May;47(5):872-879. doi: 10.1002/eji.201646775. Epub 2017 Apr 10.

18.

Roquin Paralogs Differentially Regulate Functional NKT Cell Subsets.

Drees C, Vahl JC, Bortoluzzi S, Heger KD, Fischer JC, Wunderlich FT, Peschel C, Schmidt-Supprian M.

J Immunol. 2017 Apr 1;198(7):2747-2759. doi: 10.4049/jimmunol.1601732. Epub 2017 Feb 10.

19.

Niche WNT5A regulates the actin cytoskeleton during regeneration of hematopoietic stem cells.

Schreck C, Istvánffy R, Ziegenhain C, Sippenauer T, Ruf F, Henkel L, Gärtner F, Vieth B, Florian MC, Mende N, Taubenberger A, Prendergast Á, Wagner A, Pagel C, Grziwok S, Götze KS, Guck J, Dean DC, Massberg S, Essers M, Waskow C, Geiger H, Schiemann M, Peschel C, Enard W, Oostendorp RA.

J Exp Med. 2017 Jan;214(1):165-181. doi: 10.1084/jem.20151414. Epub 2016 Dec 20.

20.

Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.

Bassani-Sternberg M, Bräunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K, Martignoni ME, Werner A, Hein R, H Busch D, Peschel C, Rad R, Cox J, Mann M, Krackhardt AM.

Nat Commun. 2016 Nov 21;7:13404. doi: 10.1038/ncomms13404.

21.

Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.

Spoerl S, Peter R, Wäscher D, Götze K, Verbeek M, Peschel C, Krackhardt AM.

Transfusion. 2017 Jan;57(1):115-121. doi: 10.1111/trf.13883. Epub 2016 Nov 18.

PMID:
27859332
22.

Use of Complementary and Alternative Medicine (CAM) as Part of the Oncological Treatment: Survey about Patients' Attitude towards CAM in a University-Based Oncology Center in Germany.

Kessel KA, Lettner S, Kessel C, Bier H, Biedermann T, Friess H, Herrschbach P, Gschwend JE, Meyer B, Peschel C, Schmid R, Schwaiger M, Wolff KD, Combs SE.

PLoS One. 2016 Nov 3;11(11):e0165801. doi: 10.1371/journal.pone.0165801. eCollection 2016.

23.

RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells.

Höckendorf U, Yabal M, Herold T, Munkhbaatar E, Rott S, Jilg S, Kauschinger J, Magnani G, Reisinger F, Heuser M, Kreipe H, Sotlar K, Engleitner T, Rad R, Weichert W, Peschel C, Ruland J, Heikenwalder M, Spiekermann K, Slotta-Huspenina J, Groß O, Jost PJ.

Cancer Cell. 2016 Jul 11;30(1):75-91. doi: 10.1016/j.ccell.2016.06.002.

24.

Immuno-PET Imaging of Engineered Human T Cells in Tumors.

Mall S, Yusufi N, Wagner R, Klar R, Bianchi H, Steiger K, Straub M, Audehm S, Laitinen I, Aichler M, Peschel C, Ziegler S, Mustafa M, Schwaiger M, D'Alessandria C, Krackhardt AM.

Cancer Res. 2016 Jul 15;76(14):4113-23. doi: 10.1158/0008-5472.CAN-15-2784. Epub 2016 Jun 28.

25.

USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma.

Engel K, Rudelius M, Slawska J, Jacobs L, Ahangarian Abhari B, Altmann B, Kurutz J, Rathakrishnan A, Fernández-Sáiz V, Brunner A, Targosz BS, Loewecke F, Gloeckner CJ, Ueffing M, Fulda S, Pfreundschuh M, Trümper L, Klapper W, Keller U, Jost PJ, Rosenwald A, Peschel C, Bassermann F.

EMBO Mol Med. 2016 Aug 1;8(8):851-62. doi: 10.15252/emmm.201506047. Print 2016 Aug.

26.

Loss of Sfrp2 in the Niche Amplifies Stress-Induced Cellular Responses, and Impairs the In Vivo Regeneration of the Hematopoietic Stem Cell Pool.

Ruf F, Schreck C, Wagner A, Grziwok S, Pagel C, Romero S, Kieslinger M, Shimono A, Peschel C, Götze KS, Istvanffy R, Oostendorp RA.

Stem Cells. 2016 Sep;34(9):2381-92. doi: 10.1002/stem.2416. Epub 2016 Jun 30.

27.

Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.

Eichner R, Heider M, Fernández-Sáiz V, van Bebber F, Garz AK, Lemeer S, Rudelius M, Targosz BS, Jacobs L, Knorn AM, Slawska J, Platzbecker U, Germing U, Langer C, Knop S, Einsele H, Peschel C, Haass C, Keller U, Schmid B, Götze KS, Kuster B, Bassermann F.

Nat Med. 2016 Jul;22(7):735-43. doi: 10.1038/nm.4128. Epub 2016 Jun 13.

PMID:
27294876
28.

Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia.

Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, Slotta-Huspenina J, Steiger K, Altmann T, Weißer T, Steidle S, Schick M, Jacobs L, Slawska J, Müller-Thomas C, Verbeek M, Subklewe M, Peschel C, Wester HJ, Schwaiger M, Götze K, Keller U.

Haematologica. 2016 Aug;101(8):932-40. doi: 10.3324/haematol.2016.142976. Epub 2016 May 12.

29.

Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.

Spinner S, Crispatzu G, Yi JH, Munkhbaatar E, Mayer P, Höckendorf U, Müller N, Li Z, Schader T, Bendz H, Hartmann S, Yabal M, Pechloff K, Heikenwalder M, Kelly GL, Strasser A, Peschel C, Hansmann ML, Ruland J, Keller U, Newrzela S, Herling M, Jost PJ.

Leukemia. 2016 Jul;30(7):1520-30. doi: 10.1038/leu.2016.49. Epub 2016 Mar 8.

PMID:
27055871
30.

Characteristics and outcome of patients presenting to the emergency department after autologous/allogeneic stem cell transplantation.

Spoerl S, Hendlmeier C, Hapfelmeier A, Wildgruber M, Schmid RM, Peschel C, Saugel B.

Eur J Emerg Med. 2017 Dec;24(6):435-442. doi: 10.1097/MEJ.0000000000000391.

PMID:
27002565
31.

Stroma-Derived Connective Tissue Growth Factor Maintains Cell Cycle Progression and Repopulation Activity of Hematopoietic Stem Cells In Vitro.

Istvánffy R, Vilne B, Schreck C, Ruf F, Pagel C, Grziwok S, Henkel L, Prazeres da Costa O, Berndt J, Stümpflen V, Götze KS, Schiemann M, Peschel C, Mewes HW, Oostendorp RAJ.

Stem Cell Reports. 2015 Nov 10;5(5):702-715. doi: 10.1016/j.stemcr.2015.09.018. Epub 2015 Oct 29.

32.

Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia.

Wagner M, Oelsner M, Moore A, Götte F, Kuhn PH, Haferlach T, Fiegl M, Bogner C, Baxter EJ, Peschel C, Follows GA, Ringshausen I.

Blood. 2016 Jan 28;127(4):436-48. doi: 10.1182/blood-2015-05-646935. Epub 2015 Oct 27.

PMID:
26508782
33.

In vivo hematopoietic Myc activation directs a transcriptional signature in endothelial cells within the bone marrow microenvironment.

Franke K, Vilne B, Prazeres da Costa O, Rudelius M, Peschel C, Oostendorp RA, Keller U.

Oncotarget. 2015 Sep 8;6(26):21827-39.

34.

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N.

Leukemia. 2015 Oct;29(10):2062-8. doi: 10.1038/leu.2015.212. Epub 2015 Jul 31.

35.

Long-term experiences in cryopreservation of mobilized peripheral blood stem cells using a closed-bag system: a technology with potential for broader application.

Spoerl S, Peter R, Wäscher D, Verbeek M, Menzel H, Peschel C, Krackhardt AM.

Transfusion. 2015 Nov;55(11):2702-8. doi: 10.1111/trf.13206. Epub 2015 Jul 14.

PMID:
26172379
36.

Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.

Jilg S, Reidel V, Müller-Thomas C, König J, Schauwecker J, Höckendorf U, Huberle C, Gorka O, Schmidt B, Burgkart R, Ruland J, Kolb HJ, Peschel C, Oostendorp RA, Götze KS, Jost PJ.

Leukemia. 2016 Jan;30(1):112-23. doi: 10.1038/leu.2015.179. Epub 2015 Jul 8.

PMID:
26153654
37.

Serious outbreak of human metapneumovirus in patients with hematologic malignancies.

Hoellein A, Hecker J, Hoffmann D, Göttle F, Protzer U, Peschel C, Götze K.

Leuk Lymphoma. 2016;57(3):623-7. doi: 10.3109/10428194.2015.1067699. Epub 2015 Jun 30.

PMID:
26122193
38.

Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study.

Schreiber S, Hoellein A, Decker T, Jilg S, Dreyling M, Peschel C, Keller U.

Leuk Lymphoma. 2015;56(11):3227-9. doi: 10.3109/10428194.2015.1028055. Epub 2015 Mar 31. No abstract available.

PMID:
25754578
39.

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.

Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lückerath K, Pietschmann E, Habringer S, Gerngroß C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Götze K, Wester HJ, Keller U.

EMBO Mol Med. 2015 Apr;7(4):477-87. doi: 10.15252/emmm.201404698.

40.

Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells.

Illert AL, Seitz AK, Rummelt C, Kreutmair S, Engh RA, Goodstal S, Peschel C, Duyster J, von Bubnoff N.

PLoS One. 2014 Nov 26;9(11):e112318. doi: 10.1371/journal.pone.0112318. eCollection 2014.

41.

Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis.

Baumann U, Fernández-Sáiz V, Rudelius M, Lemeer S, Rad R, Knorn AM, Slawska J, Engel K, Jeremias I, Li Z, Tomiatti V, Illert AL, Targosz BS, Braun M, Perner S, Leitges M, Klapper W, Dreyling M, Miething C, Lenz G, Rosenwald A, Peschel C, Keller U, Kuster B, Bassermann F.

Nat Med. 2014 Dec;20(12):1401-9. doi: 10.1038/nm.3740. Epub 2014 Nov 24.

PMID:
25419709
42.

Cks1 is a critical regulator of hematopoietic stem cell quiescence and cycling, operating upstream of Cdk inhibitors.

Tomiatti V, Istvánffy R, Pietschmann E, Kratzat S, Hoellein A, Quintanilla-Fend L, von Bubnoff N, Peschel C, Oostendorp RA, Keller U.

Oncogene. 2015 Aug 13;34(33):4347-57. doi: 10.1038/onc.2014.364. Epub 2014 Nov 24.

PMID:
25417705
43.

GP130 activation induces myeloma and collaborates with MYC.

Dechow T, Steidle S, Götze KS, Rudelius M, Behnke K, Pechloff K, Kratzat S, Bullinger L, Fend F, Soberon V, Mitova N, Li Z, Thaler M, Bauer J, Pietschmann E, Albers C, Grundler R, Schmidt-Supprian M, Ruland J, Peschel C, Duyster J, Rose-John S, Bassermann F, Keller U.

J Clin Invest. 2014 Dec;124(12):5263-74. doi: 10.1172/JCI69094. Epub 2014 Nov 10.

44.

Grb10 is involved in BCR-ABL-positive leukemia in mice.

Illert AL, Albers C, Kreutmair S, Leischner H, Peschel C, Miething C, Duyster J.

Leukemia. 2015 Apr;29(4):858-68. doi: 10.1038/leu.2014.283. Epub 2014 Sep 24.

PMID:
25249015
45.

Clinical challenge: fatal mucormycotic osteomyelitis caused by Rhizopus microsporus despite aggressive multimodal treatment.

Harrasser N, Banke IJ, Hauschild M, Lenze U, Prodinger PM, Toepfer A, Peschel C, von Eisenhart-Rothe R, Ringshausen I, Verbeek M.

BMC Infect Dis. 2014 Sep 6;14:488. doi: 10.1186/1471-2334-14-488.

46.

Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.

Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, Laitinen I, Nilsson L, Goga A, Peschel C, Nilsson JA, Cleveland JL, Keller U.

Blood. 2014 Sep 25;124(13):2081-90. doi: 10.1182/blood-2014-06-584524. Epub 2014 Aug 20.

47.

Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer.

Löhr JM, Haas SL, Kröger JC, Friess HM, Höft R, Goretzki PE, Peschel C, Schweigert M, Salmons B, Gunzburg WH.

Pharmaceutics. 2014 Aug 11;6(3):447-66. doi: 10.3390/pharmaceutics6030447. Review.

48.

Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.

Heidegger S, Beer AJ, Geissinger E, Rosenwald A, Peschel C, Ringshausen I, Keller U.

Onco Targets Ther. 2014 Jun 20;7:1123-7. doi: 10.2147/OTT.S59795. eCollection 2014.

49.

Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL.

Herrmann K, Buck AK, Schuster T, Abbrederis K, Blümel C, Santi I, Rudelius M, Wester HJ, Peschel C, Schwaiger M, Dechow T, Keller U.

Oncotarget. 2014 Jun 30;5(12):4050-9.

50.

Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

Müller-Thomas C, Rudelius M, Rondak IC, Haferlach T, Schanz J, Huberle C, Schmidt B, Blaser R, Kremer M, Peschel C, Germing U, Platzbecker U, Götze K.

Haematologica. 2014 Oct;99(10):e179-81. doi: 10.3324/haematol.2014.104760. Epub 2014 Jun 27. No abstract available.

Supplemental Content

Loading ...
Support Center